To include your compound in the COVID-19 Resource Center, submit it here.

NewLink, AZ partner for IDO/PD-L1 pancreatic cancer combo trial

NewLink Genetics Corp. (NASDAQ:NLNK) partnered with AstraZeneca plc (LSE:AZN; NYSE:AZN) to conduct a Phase II trial evaluating a combination of NewLink's indoximod (NLG8189),

Read the full 237 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE